somapacitan-beco (Sogroya)

Indications

• treatment of adults with growth hormone deficiency

Contraindications

• severe or proliferative diabetic retinopathy
• malignancy
• critical illness

Dosage

• start 1.5 mg SQ weekly into thigh or abdomen (rotate injection sites)
• increase dose 0.5-1.5 mg every 2-4 weeks until desired dose reached
• titrate to clinical effect & serum IGF-1
• maximum 8 mg weekly

Injection: 10 mg/1.5 mL (6.7 mg/mL)b. single patient use prefilled pen

Adverse effects

• lipohypertrophy/lipoatrophy at injection site (rotate injection site regularly)
• increased risk of neoplasm
• hyperglycemia, diabetes mellitus & complications of diabetes mellitus
• intracranial hypertension (usually within 8 weeks of initiation)
• hypersensitivity
• fluid retention (edema)
• hypoadrenalism
• hypothyroidism
• pancreatitis
• back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, weight increase, anemia
• increased serum creatine phosphokinase

Laboratory

• monitor serum IGF-1
• serum glucose
• serum cortisol
• serum TSH

Mechanism of action

• human growth hormone analog

More general terms

• recombinant protein; chimer
• metabolic agent (metabolic modifier)

Patient information

somapacitan-beco (Sogroya) patient information